The 2020 Annual Meeting of the American Society of Clinical Oncology (ASCO) was held virtually in May. While ASCO remains more focused on the latest research in solid tumors, there were several worthwhile abstracts related to CLL. Dr. Koffman takes us through his “Top 12” abstracts in short videos with accompanying text. Here are numbers 12, 11, and 10.
ASCO 2020 Top 12
#12 The shift in therapies for the treatment of CLL patients in the US Veterans Health Administration
Wonderful how you can provide all of this complex information from scores of intense studies to this audience in such a clear and concise way that is easily to understand.
In regard to ROR1, I would like to nominate Dr. Thomas Kipps to receive the nickname "RORY".
It seems the more that is discovered, the more there is known for possible targets and resistance. It would exciting if the trigger source could be discovered and overcome. E.g a code in the DNA.
I recall watching a hematologic symposium where they were discussing how they were customizing NK cells to attack specific targets by adding programmed receptors. These cells were instructed for apoptosis when they ran out of target cells.
Fascinating, but far beyond my thought capability.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.
Test Before Treat
Zanubrutinib-Gazyva Shows Promise for CLL/SLL
